Ozempic Face is primarily caused by rapid weight loss, and the changes GLP-1 drugs make to our body composition of fat, muscle, and water
Preprint at medRxiv (2023)
Inflammatory Microenvironment Research Both peptides are theorized to support the inflammatory milieu: BPC157 is believed to modulate cytokine signaling to support controlled inflammation and repair, while TB500 seems to reduce chronic inflammatory signaling and support tissue pliability
Its a triple-agonist peptide , meaning it activates three major systems simultaneously: GLP-1 reduces hunger and slows digestion GIP enhances metabolic efficiency Glucagon increases energy expenditure This combination leads to: Eating less without constant willpower Better blood sugar regulation Increased calorie burn at rest The clinical data is already strong Even in earlier trials, the results were hard to ignore: Up to ~24% total body weight loss in Phase 2 studies Around 17% weight loss in type 2 diabetes patients , alongside improved glucose control Up to 82% reduction in liver fat in individuals with fatty liver disease This isnt just weight lossits full metabolic change
It quietly does three big things: Signals your brain when youre full so you naturally stop eating
These preclinical observations in rodents promote continued study with the aim of translation to larger animals and specifically primates, the central focus being the quantification of therapeutic index when administered for sustained periods